A review of oxaliplatin and its clinical use in colorectal cancer

Axel F Grothey, Richard M. Goldberg

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Colorectal cancer is one of the leading causes of death from malignant diseases in the Western world. Worldwide, ∼50% of patients who present with colorectal cancer will develop metastatic disease and eventually die from this malignancy. Recently, significant advances have been made in the medical treatment of advanced colorectal cancer with the introduction of novel cytotoxic drugs, such as irinotecan and oxaliplatin. Based on the results of recent Phase III trials, combination regimens of infusional 5-fluorouracil/leucovorin and oxaliplatin (FOLFOX) have emerged as a new standard of care in the palliative and adjuvant treatment of colorectal cancer. The addition of biological agents targeting angiogenesis or oncogenes such as epidermal growth factor receptor (EGFR) to FOLFOX will conceivably further enhance the activity of treatment regimens. Making use of all available active therapeutic options in the course of disease has significantly improved median overall survival of metastatic colorectal cancer into a chronic disease, with implications for treatment strategies and pharmacoeconomic considerations. 2004

Original languageEnglish (US)
Pages (from-to)2159-2170
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume5
Issue number10
DOIs
StatePublished - Oct 2004

Fingerprint

oxaliplatin
Colorectal Neoplasms
irinotecan
Pharmaceutical Economics
Western World
Leucovorin
Biological Factors
Therapeutics
Standard of Care
Palliative Care
Oncogenes
Epidermal Growth Factor Receptor
Fluorouracil
Cause of Death
Chronic Disease

Keywords

  • Adjuvant
  • Chemotherapy
  • Colorectal cancer
  • Oxaliplatin
  • Palliative

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

A review of oxaliplatin and its clinical use in colorectal cancer. / Grothey, Axel F; Goldberg, Richard M.

In: Expert Opinion on Pharmacotherapy, Vol. 5, No. 10, 10.2004, p. 2159-2170.

Research output: Contribution to journalArticle

Grothey, Axel F ; Goldberg, Richard M. / A review of oxaliplatin and its clinical use in colorectal cancer. In: Expert Opinion on Pharmacotherapy. 2004 ; Vol. 5, No. 10. pp. 2159-2170.
@article{649888de20384614acb811f7a67fc991,
title = "A review of oxaliplatin and its clinical use in colorectal cancer",
abstract = "Colorectal cancer is one of the leading causes of death from malignant diseases in the Western world. Worldwide, ∼50{\%} of patients who present with colorectal cancer will develop metastatic disease and eventually die from this malignancy. Recently, significant advances have been made in the medical treatment of advanced colorectal cancer with the introduction of novel cytotoxic drugs, such as irinotecan and oxaliplatin. Based on the results of recent Phase III trials, combination regimens of infusional 5-fluorouracil/leucovorin and oxaliplatin (FOLFOX) have emerged as a new standard of care in the palliative and adjuvant treatment of colorectal cancer. The addition of biological agents targeting angiogenesis or oncogenes such as epidermal growth factor receptor (EGFR) to FOLFOX will conceivably further enhance the activity of treatment regimens. Making use of all available active therapeutic options in the course of disease has significantly improved median overall survival of metastatic colorectal cancer into a chronic disease, with implications for treatment strategies and pharmacoeconomic considerations. 2004",
keywords = "Adjuvant, Chemotherapy, Colorectal cancer, Oxaliplatin, Palliative",
author = "Grothey, {Axel F} and Goldberg, {Richard M.}",
year = "2004",
month = "10",
doi = "10.1517/14656566.5.10.2159",
language = "English (US)",
volume = "5",
pages = "2159--2170",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - A review of oxaliplatin and its clinical use in colorectal cancer

AU - Grothey, Axel F

AU - Goldberg, Richard M.

PY - 2004/10

Y1 - 2004/10

N2 - Colorectal cancer is one of the leading causes of death from malignant diseases in the Western world. Worldwide, ∼50% of patients who present with colorectal cancer will develop metastatic disease and eventually die from this malignancy. Recently, significant advances have been made in the medical treatment of advanced colorectal cancer with the introduction of novel cytotoxic drugs, such as irinotecan and oxaliplatin. Based on the results of recent Phase III trials, combination regimens of infusional 5-fluorouracil/leucovorin and oxaliplatin (FOLFOX) have emerged as a new standard of care in the palliative and adjuvant treatment of colorectal cancer. The addition of biological agents targeting angiogenesis or oncogenes such as epidermal growth factor receptor (EGFR) to FOLFOX will conceivably further enhance the activity of treatment regimens. Making use of all available active therapeutic options in the course of disease has significantly improved median overall survival of metastatic colorectal cancer into a chronic disease, with implications for treatment strategies and pharmacoeconomic considerations. 2004

AB - Colorectal cancer is one of the leading causes of death from malignant diseases in the Western world. Worldwide, ∼50% of patients who present with colorectal cancer will develop metastatic disease and eventually die from this malignancy. Recently, significant advances have been made in the medical treatment of advanced colorectal cancer with the introduction of novel cytotoxic drugs, such as irinotecan and oxaliplatin. Based on the results of recent Phase III trials, combination regimens of infusional 5-fluorouracil/leucovorin and oxaliplatin (FOLFOX) have emerged as a new standard of care in the palliative and adjuvant treatment of colorectal cancer. The addition of biological agents targeting angiogenesis or oncogenes such as epidermal growth factor receptor (EGFR) to FOLFOX will conceivably further enhance the activity of treatment regimens. Making use of all available active therapeutic options in the course of disease has significantly improved median overall survival of metastatic colorectal cancer into a chronic disease, with implications for treatment strategies and pharmacoeconomic considerations. 2004

KW - Adjuvant

KW - Chemotherapy

KW - Colorectal cancer

KW - Oxaliplatin

KW - Palliative

UR - http://www.scopus.com/inward/record.url?scp=6444225487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6444225487&partnerID=8YFLogxK

U2 - 10.1517/14656566.5.10.2159

DO - 10.1517/14656566.5.10.2159

M3 - Article

C2 - 15461551

AN - SCOPUS:6444225487

VL - 5

SP - 2159

EP - 2170

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 10

ER -